Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
10 janv. 2024 19h30 HE
|
Sermonix Pharmaceuticals Inc.
Partnership expands Henlius’ portfolio with license of exclusive China rights to develop, manufacture and commercialize lasofoxifene; Sermonix retains all other global rightsHenlius to facilitate...